Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, has announced it entered into a secured debt facility upsizing with Hercules Capital and royalty financing agreement with DRI Healthcare, and accelerated its timelines for the submission of the veligrotug BLA and the topline clinical data readouts of its VRDN-003 REVEAL trials in patients with thyroid eye disease (TED).
Latham & Watkins LLP represents Hercules in the transaction with a deal team led by partners Dan Van Fleet and Haim Zaltzman with counsel Emily Yu and associates Hyunji Lee and Scott Natsuhara. Advice was also provided on tax matters by partner Eric Cho; and on converts matters by partner Eric Rice.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.